- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00158548
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The incidence of falciparum malaria in Pakistan has risen 6-fold over the last 15 years and chloroquine resistance is prevalent in every malarious area examined. Chloroquine's position as first line treatment must be reconsidered. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine SP, is 10% and rising fast. It is critical to preserve the effective life of SP by using it in combination with a non-related fast-acting antimalarial such as artesunate (AS). It is conceivable that use of AS in combination with chloroquine itself might even recover the latter's effectiveness and restrain the selection of stronger levels of chloroquine resistance. To determine the tolerability and efficacy of AS combination therapy in the subcontinent, randomized controlled trials will be conducted by HealthNet International and government staff, with technical support from LSHTM, in Afghan refugee camps in Pakistan against the current therapies of chloroquine, amodiaquine and SP. Current policy is to use primaquine(PQ) as the gametocytocidal drug with CQ or SP. It is not clear whether this has any value in the face of high levels of CQ resistance. The efficacy of PQ in combination with CQ or SP will be examined in individual randomised trial in comparison with CQ or SP alone.
In the past, treatment of falciparum and vivax malaria was with chloroquine. With development of drug resistance treatment of the two species is diverging and this places higher priority on accurate differential diagnosis which cannot always be met at peripheral health posts. There may be advantage in harmonising treatment of the two species with ACT. Thus the current treatment for vivax, chloroquine, shall be compared with that of ACT with artesunate and SP, the likely ACT to be adopted for falciparum malaria.
Protocol design:
Randomised, single-blind, controlled trials comparing for falciparum malaria (1) artesunate (AS) and chloroquine (CQ), vs CQ alone, vs CQ and primaquine (PQ); (2) AS and sulphadoxine-pyrimethamine (SP), vs SP alone, vs SP and PQ; (3) AS and amodiaquine (AQ), vs AQ alone.
Randomised, single-blind, controlled trial comparing for vivax malaria: AS and sulphadoxine-pyrimethamine (SP), vs CQ alone.
Patients will be randomly assigned to one of the following treatment groups:
- CQ (day1,2,3) + placebo (day 1, 3) vs
- CQ (day 1,2,3) + PQ (day 1) + placebo (day 3) vs
- CQ (day 1,2,3) + PQ (day 3) + placebo (day 1) vs
- CQ (day 1,2,3) + AS (day 1) + placebo (day 3)
- S/P (day 1) + placebo (day 1) vs
- S/P (day 1) + AS (day 1) vs
- S/P (day 1) + PQ (day 1)
- AQ (day 1,2,3) + placebo (day 1,2,3) vs
- AQ (day 1,2,3) + AS (day 1,2,3)
To determine the viability and transmissibility of any gametocytes (and also to detect sub-patent gametocytaemias) still present after treatment it is also proposed to carry out mosquito feeding studies directly on patients on the 7th day after the start of combination therapy with either CQ, CQ+AS, CQ+PQ., SP, SP+AS, SP+PQ and to incubate any midgut infections to the oocyst stage. To determine the genetic consequences of any selection from the different drugs (i.e. CQ, AS, or PQ), the mosquito midgut infections would be preserved for further genetic studies in UK, as would blood samples taken from initial and recrudescent infections.
To improve our understanding of the genetic basis of drug resistance we will genotype parasites from blood samples of patients with treatment failure in this study. Blood samples of 20 patients from each arm of the study who had parasitological treatment failure will be selected randomly, together with midgut infections, and analysed for genetic markers of resistance to chloroquine and sulphadoxine/pyrimethamine. These will be compared with genotypes of pre-treatment infections.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Peshawar, Pakistan
- HealthNet International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults or children > 5 yrs
- weight > 5 kg
- monoinfection with P. falciparum or P. vivax
- history of recent fever
- consent from patient or parent.
Exclusion Criteria:
- patients with signs of severe malaria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Day 7 slide clearance rate (complete clearance of trophozoites) assessed by microscopists who are blind to treatment allocation.
|
Day 28 slide clearance rate without subsequent recrudescence.
|
Day 7 gametocyte prevalence.
|
Secondary Outcome Measures
Outcome Measure |
---|
Fever clearance time
|
Day 14 gametocyte prevalence
|
cure rate (elimination of parasitaemia without recrudescence).
|
Rate and time of parasite clearance.
|
Rate of resolution of fever.
|
Proportion of gametocyte carriers.
|
Transmissibility of gametocytes through mosquito feeding studies.
|
Tolerability.
|
Molecular characterisation of genetic diversity and resistance before and after treatment.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kate Graham, MSc, HealthNet International, Peshawar, Pakistan
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Malaria, Falciparum
- Malaria, Vivax
- Anti-Infective Agents
- Antiviral Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Chloroquine
- Primaquine
- Artesunate
- Amodiaquine
Other Study ID Numbers
- ITDCVC98
- ITDCVV98
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaThailand
Clinical Trials on SP, chloroquine, amodiaquine, primaquine, artesunate
-
University of OxfordMahidol University; Indonesia-MoHCompletedVivax MalariaIndonesia
-
Professor Anders BjörkmanUppsala University; Ministry of Health and Social Welfare, Zanzibar; Zanzibar...CompletedPlasmodium Falciparum MalariaTanzania
-
London School of Hygiene and Tropical MedicineCompleted
-
London School of Hygiene and Tropical MedicineMedical Research Council; National Malaria Control Programme, The GambiaCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompleted
-
London School of Hygiene and Tropical MedicineCompleted
-
PATHMahidol Oxford Tropical Medicine Research UnitTerminated
-
London School of Hygiene and Tropical MedicineNational Institute for Medical Research, TanzaniaCompleted
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand